| Document |
Document Title |
|
WO/2014/164684A1 |
Disclosed are compositions and method for delivering a target protein into a cells. The compositions, which are used in the methods of the invention, include fusion proteins comprising a repeat sequence of DSS.
|
|
WO/2014/164519A1 |
Methods and compositions are provided for reducing the effects of amyloid beta (Aβ) oligomers on a cell. Aspects of the methods generally include providing an agent that prevents Aβ oligomer activation of PirB/LILRB2 protein on cells, ...
|
|
WO/2014/160171A2 |
Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation reg...
|
|
WO/2014/154336A1 |
The technology pertains to microtiter plate-based microarrays suitable for simultaneous detection of a plurality of different selected targets in a biological sample obtained from a subject. In particular, in-vitro methods are disclosed ...
|
|
WO/2014/143087A1 |
The present disclosure is directed to individual Aß peptide immunogen constructs, peptide compositions comprising these Aß peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations co...
|
|
WO/2014/142020A1 |
This nucleic acid linker is for preparing a complex of mRNA2 and a protein or peptide (33) encoded by mRNA2, and is characterized by being provided, on the 5' terminal, with a spacer moiety (51c), a polynucleotide moiety (51a) obtained b...
|
|
WO/2014/133327A1 |
The present invention relates to: an insulin conjugate, wherein a non-peptidic polymer and an immunoglobulin Fc region are site-selectively connected, by a covalent bond, to an amino acid residue of a region excluding the N terminal of i...
|
|
WO/2014/130949A1 |
The present invention relates to methods and compositions for treating disease related to disorders of bone remodeling. In particular, the present invention relates to compositions and methods for treating rheumatoid arthritis.
|
|
WO/2014/126230A1 |
The objective of the present invention is to provide a competitive enzyme immunoassay (EIA) method which can quantitatively measure indoxyl sulfate in the blood. This competitive method for measuring indoxyl sulfate includes: (1) a ste...
|
|
WO/2014/125955A1 |
The present invention provides a method for refolding an antibody, a process for producing a refolded antibody, a refolded antibody, and uses of these. This method, which is for refolding an antibody in a liquid phase, and the process fo...
|
|
WO/2014/113802A1 |
Disclosed are molecules for treating non-del(5q) MDS that mimic allelic deficiency in del5q MDS to sensitize the malignant clones of patient without del(5q). The disclosed molecule contains an inhibitor of Cdc25C, an inhibitor of PP2Acα...
|
|
WO/2014/100377A1 |
The invention provides methods for delivery of payloads to targets in samples using mixed payload polymers. The invention further provides reagents and kits for practicing the methods of the invention. The invention also provides methods...
|
|
WO/2014/087937A1 |
Provided is a separating agent which comprises a carrier and a ligand that is supported on the surface of the carrier by means of a chemical bond. This separating agent is characterized in that: the carrier is a core-shell particle that ...
|
|
WO/2014/082132A1 |
The present invention relates to microparticles, methods of producing microparticles and microparticle precursor compositions. In particular, it relates to microparticles comprising a protective matrix and a protective matrix precursor c...
|
|
WO/2014/085637A1 |
The present invention concerns novel antibiotic compounds, which are lantibiotics, the processes for their preparation, their pharmaceutically acceptable salts, pharmaceutical compositions containing the lantibiotics, and their use as an...
|
|
WO/2014/084421A1 |
The present invention relates to a method for preparing an end site-specific macromolecule-bile acid oligomer conjugate, comprising conjugating a bile acid oligomer which is prepared by oligomerization of two or more bile acid monomers t...
|
|
WO/2014/068991A1 |
The present invention relates to the field of a novel polyamine transporter. According to the present invention, a transporter that carries out polyamine transport and a gene that encodes the same are identified. In addition, according t...
|
|
WO/2014/056896A2 |
The invention relates to a method for covalent immobilisation of a biomolecule to a solid material and products arising therefrom, comprising providing a solid material with an activated surface, preferably by treatment with an oxidising...
|
|
WO/2014/046278A1 |
The present invention addresses the problem of developing technology for creating new modified protein ligands that maximize binding capacity and binding efficiency to a target molecule when a protein ligand is immobilized in an affinity...
|
|
WO/2014/041124A1 |
The invention relates to an immobilisation matrix comprising a tetraether lipid layer, on which ligands (capture molecules) that can bond to a target can be covalently immobilised. The invention also relates to the method for producing s...
|
|
WO/2014/038168A1 |
Provided are: a functional substance which has high permeability into a living body and, therefore, is capable of efficiently supplying a bioactive molecule into a part such as the brain of the living body; and a method for penetrating a...
|
|
WO/2014/035333A1 |
The present invention relates to an artificial cell membrane system comprising at least one membrane protein carrier associated with at least one membrane protein, wherein the at least one membrane protein carrier comprises or consists o...
|
|
WO/2014/026271A1 |
A method of producing a radial chemical gradient on a surface of a substrate involves controllably forcing a predetermined amount of a chemical compound through an orifice in the substrate. The orifice connects a surface on which the gra...
|
|
WO/2014/028502A1 |
The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides nove...
|
|
WO/2014/021240A1 |
The purpose of the present invention is to provide an excellent protein that maintains high antibody binding activity under neutrality but has a lower bindability with the Fc region and/or bindability with the Fab region of immunoglobuli...
|
|
WO/2014/008363A1 |
A nanoplasmonic platform can be used for the detection and quantification of multiple HIV subtypes in whole blood with localized surface plasmon resonance. Among other things, this nanoplasmonic platform provides a viable way to detectio...
|
|
WO/2014/000749A1 |
This patent involves production to two novel carriers based on safe and natural blend of grafted biopolymers for encapsulation of enzymes and polyunsaturated fatty acid (PUFA), which are enriched in vegetables and fish oils. Encapsulatio...
|
|
WO/2013/185178A1 |
The invention relates to nanoemulsions useful for analytical techniques and delivery of cargoes such as pharmaceutically active agents. In particular, the invention relates to nanoemulsions comprising an oil phase dispersed in an aqueous...
|
|
WO/2013/187398A1 |
The purpose of the present invention is to provide: a support onto which Protein A has been immobilized, the Protein A having a specific amino acid sequence that enables the dissociation of antibodies under mild pH conditions (specifical...
|
|
WO/2013/180253A1 |
Provided are: a pH-sensitive carrier which can be used as a carrier for a physiologically active substance and can respond to a weakly acidic environment to exhibit an effect of promoting a membrane-disrupting function; a method for prod...
|
|
WO/2013/177197A1 |
The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell ...
|
|
WO/2013/177231A1 |
Disclosed is a new approach for delivering compounds and drugs to the cytosol of living cells through the use of engineered protein transporters. The engineered protein transporters include a pore and a pore specific delivery protein, wh...
|
|
WO/2013/173676A1 |
In certain embodiments, this disclosure relates to pharmaceutical formulations for polypeptide and lipophilic moiety conjugates suitable for injection into humans and other animals and methods of preparation. In certain embodiments, the ...
|
|
WO/2013/173778A1 |
Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of ...
|
|
WO/2003/023002A9 |
|
|
WO/2002/074973A9 |
|
|
WO/2013/152418A1 |
A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth facto...
|
|
WO/2013/147233A1 |
The present invention provides the following: a method for efficiently producing a reagent for detecting an antibody that specifically binds with an insoluble antigen protein present in a liquid sample; a reagent for antibody detection p...
|
|
WO/2013/139993A1 |
The present invention refers to a modified phalloidin, which may be coupled via the primary group at side chain 7 to a labelling group or a matrix, which may bind with high affinity to filamentous actin (F-actin). The compound and the ma...
|
|
WO/2013/127816A1 |
Herein is reported a method for obtaining a polypeptide by an immobilized metal ion affinity chromatography from a pro-polypeptide that comprise at its N- or C-terminus an metal ion affinity chromatography tag and a protease cleavage sit...
|
|
WO/2013/122061A1 |
The purpose of the present invention is to provide: a peptide having affinity for silicon nitride; the polynucleotide encoding said peptide; an expression vector for the peptide having affinity for silicon nitride; an expression vector f...
|
|
WO/2013/117880A1 |
As shown in Figure 4, substrate (1) has printed areas on it and these areas include a biological molecule which has been printed on the surface using a rotary printing press methods to allow for rapid and high quality printing. The print...
|
|
WO/2013/119061A1 |
The present invention relates to a dosage form for the transdermal delivery of drugs, and to a method for manufacturing same. More specifically, the present invention relates to: a method for manufacturing a drug delivery vector for tran...
|
|
WO/2013/113107A1 |
Methods of stimulating neuron survival, axon growth and/or promoting axon regeneration of a neogenin expressing cell in a subject in need thereof are provided. The methods involve for example, administering to a subject in need thereof a...
|
|
WO/2013/110163A1 |
Compositions for and methods of stimulating a M HC I mediated immune response comprising stimulating MHC I endolysosomal cross presentation in dendritic cells. Stimulation MHC I endolysosomal cross presentation may comprise over-expressi...
|
|
WO/2013/108983A1 |
The present invention relates to a pH-reactive high-density lipoprotein (HDL)-like particle complex, and more specifically, to a high-density lipoprotein-like particle complex comprising apolipoprotein A-I (apoA-I) and a drug trapped the...
|
|
WO/2013/081037A1 |
The present invention relates to a peptide which contains an amino acid sequence consisting of 14 to 18 amino acid residues and capable of binding to human IgA, and an analysis or purification method for the human IgA which uses the pept...
|
|
WO/2013/078091A1 |
The present invention provides both a caged collagen mimetic peptide (CCMP) having the formula: L-S-Zm-[Gly-X-Y]n- LGly -X-Y-[Gly-X-Y]n; wherein L is one or more detectable moieties and/or biologically active compounds; S is one or more ...
|
|
WO/2013/075600A1 |
Disclosed are a polyethylene glycol-modified polypeptide and the use thereof in the preparation of drugs for tumour treatment. The polypeptide has the function of inhibiting tumour angiogenesis and is an integrin blocker with affinity an...
|
|
WO/2013/071440A1 |
Methods and products (e.g., recombinant proteins) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering ...
|
